AHFS (R) Drug Information (R) 2024

With new and extensively updated information on everything from current treatment guidelines to off-label uses, AHFS Drug Information (R) 2024 is a necessary addition to your pharmacy's resources.AHFS (R) DI (TM) contains the most dependable drug information available-all in one place. It is the most comprehensive evidence-based source of drug information complete with ongoing updates of therapeutic guideline recommendations, important cautionary information, and other timely and relevant topics related to drug therapy management.Updates in this edition include:Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines.Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments.Contemporary topics such as changes in mifepristone REMS requirements, off-label use of misoprostol, and ongoing alterations to use of the COVID-19 vaccines.Expanded firstRelease documents for gene therapies.Updates to a variety of vaccine monographs including the pneumococcal, rabies, and respiratory syncytial virus vaccines.Expanded content on off-label uses and long-term clinical data.MedWatch alerts, Standardize4Safety information, REMS data, and focused FDA updates for various medications.New content on over 100 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 150 medications.